{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:41:09Z","timestamp":1782996069712,"version":"3.54.5"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>The study aimed to explore the coexisting patterns and assess the significance of serum hepatitis B virus (HBV) RNA and traditional virological biomarkers in patients with antiviral treatment-na\u00efve chronic hepatitis B virus (HBV) infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Serum HBV RNA, HBV DNA, hepatitis B surface antigen (HBsAg), and hepatitis B envelope antigen (HBeAg) levels were measured and compared in patients with chronic hepatitis B virus infection. The HBV RNA levels were determined using a simultaneous amplification and testing assay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the HBeAg-negative (HBeAg [\u2212]) patients, the serum HBV RNA detectable (HBV RNA [+]) rate (33.33%, 14\/42) was significantly lower than the serum HBV DNA detectable (HBV DNA [+]) rate (95.24%, 40\/42; <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001). However, there was no significant difference in the HBeAg-positive (HBeAg [+]) patients (<jats:italic>p<\/jats:italic>\u202f&amp;gt;\u202f0.05). The HBV RNA (+) rate (33.33%, 14\/42) was lower in the HBeAg-negative patients than in the HBeAg-positive patients (100%, 17\/17, <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001), while the HBV DNA (+) rate (95.24%, 40\/42 vs. 94.12%, 16\/17) showed no significant difference (<jats:italic>p<\/jats:italic>\u202f&amp;gt;\u202f0.05). The HBV RNA (+) rates showed a significant difference (<jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001) among the different HBsAg levels (10.00, 65.00, 84.21%, <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001), while the HBV DNA (+) rate showed no significant difference (<jats:italic>p<\/jats:italic>\u202f&amp;gt;\u202f0.05). In all patients, serum HBV RNA correlated well with HBV DNA (<jats:italic>r<\/jats:italic>\u202f=\u202f0.72, <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001), HBeAg (<jats:italic>r<\/jats:italic>\u202f=\u202f0.68, <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001), and HBsAg (<jats:italic>r<\/jats:italic>\u202f=\u202f0.66, <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001). However, the correlations between HBV RNA and other biomarkers varied across the different HBsAg and HBeAg levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The coexisting patterns of serum HBV RNA and HBV DNA varied with the levels of HBeAg and HBsAg in the patients with treatment-na\u00efve chronic HBV infection. This further suggests that serum HBV RNA should be included in the key index panel to accurately evaluate the natural history of HBV infection and the effects of antiviral treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1525476","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T06:12:31Z","timestamp":1736316751000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Coexisting patterns and significance of serum HBV RNA and HBV DNA in patients with treatment-na\u00efve chronic hepatitis B virus infection"],"prefix":"10.3389","volume":"11","author":[{"given":"Kun-yan","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-cheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the global burden of disease study 2019","volume":"7","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s12072-021-10153-2","article-title":"High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B","volume":"15","author":"Duan","year":"2021","journal-title":"Hepatol Int"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"101563","DOI":"10.1016\/j.clinre.2020.10.008","article-title":"Combination of quantitative hepatitis B core antibody (qHBcAb) and aspartate aminotransferase (AST) can accurately diagnose immune tolerance of chronic hepatitis B virus infection based on liver biopsy","volume":"45","author":"Chi","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e1008945","DOI":"10.1371\/journal.ppat.1008945","article-title":"Biogenesis and molecular characteristics of serum hepatitis B virus RNA","volume":"16","author":"Sheng","year":"2020","journal-title":"PLoS Pathog"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/hep.30325","article-title":"Serum hepatitis B virus RNA: a new potential biomarker for chronic hepatitis B virus infection","volume":"69","author":"Liu","year":"2019","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1002\/jmv.25792","article-title":"Reverse transcriptase droplet digital PCR vs reverse transcriptase quantitative real-time PCR for serum HBV RNA quantification","volume":"92","author":"Limothai","year":"2020","journal-title":"J Med Virol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1002\/hep.32018","article-title":"Comparison of HBV RNA and hepatitis B Core related antigen with conventional HBV markers among untreated adults with chronic hepatitis B in North America","volume":"74","author":"Ghany","year":"2021","journal-title":"Hepatology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e161818","DOI":"10.1172\/JCI161818","article-title":"Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment","volume":"132","author":"Grudda","year":"2022","journal-title":"J Clin Invest"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1002\/jmv.24841","article-title":"Smaller reduction of hepatitis B virus DNA in liver tissue than in serum in patients losing HBeAg","volume":"89","author":"Tripodi","year":"2017","journal-title":"Med Virol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12876-019-0966-4","article-title":"Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1093\/ofid\/ofae241","article-title":"Profiles of HBcrAg and pgRNA in pregnant women with chronic HBV under different disease phases and antiviral prophylaxis","volume":"11","author":"Chun-Rui","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e62079","DOI":"10.5812\/hepatmon.62079","article-title":"Characterization of serum HBV RNA in patients with untreated HBeAg-positive and -negative chronic hepatitis B infection","volume":"18","author":"Li","year":"2018","journal-title":"Hepat Mon"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s12072-019-09998-5","article-title":"Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B","volume":"14","author":"Mak","year":"2020","journal-title":"Hepatol Int"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/hep.32352","article-title":"Quantified integrated hepatitis B virus is related to viral activity in patients with chronic hepatitis B","volume":"76","author":"Erken","year":"2022","journal-title":"Hepatology"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1525476\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T06:12:34Z","timestamp":1736316754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1525476\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":14,"alternative-id":["10.3389\/fmed.2024.1525476"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1525476","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"article-number":"1525476"}}